CAS NO: | 13492-01-8 |
规格: | ≥98% |
包装 | 价格(元) |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 182.23 |
---|---|
Formula | C9H12NO2S0.5 |
CAS No. | 13492-01-8 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 5 mg/mL |
Water: 46.66 mg/mL | |
Ethanol: | |
Solubility (In vivo) | |
Synonyms | Tranylcypromine, Parnate, d-Tranylcypromine, Transamine |
In Vitro | In vitro activity: R-(+)-Tranylcypromine, (±)-Tranylcypromine, and S-(–)-Tranylcypromine competitively inhibits CYP2A6-mediated metabolism of nicotine with apparent Ki values of 0.05 μM, 0.08 μM, and 2.0 μM, respectively, in human liver microsomes. Tranylcypromine (500 μg/mL) severely inhibits bradykinin-stimulated arachidonic acid release in calf aortic endothelial cells. Tranylcypromine inhibits CYP2A6 and CYP2E1 activity with IC50 of 0.42 μM and 3 μM, respectively, in human liver microsomes. Tranylcypromine induces type II and cyclopropylbenzene type I difference spectrum in human liver microsomes. Kinase Assay: Cell Assay: |
---|---|
In Vivo | Tranylcypromine injection leads to a large, slow increase in motor activity at 5 mg/kg and 10 mg/kg compared with the saline control in male rats, although 2 mg/kg Tranylcypromine does not induce an increase. Tranylcypromine (10 mg/kg) also causes significant decreases in the number of rearing behaviors in male rats. |
Animal model | |
Formulation & Dosage | |
References | Drug Metab Dispos. 2001 Jun;29(6):897-902; Environ Health Perspect. 2004 Aug;112(11):1159-64. |